Tuhura Biosciences, Inc/nv 10-Q quarterly reports

TuHura Biosciences disclosed its Q2 2026 financial results, highlighting increased R&D spending and a substantial net loss, while also detailing a new $50 million credit facility and ongoing efforts to secure additional capital.

TuHURA Biosciences reports Q1 2026 financial results, highlighting a $7.5 million net loss and a new $50 million credit facility to support clinical development.

TuHURA Biosciences, Inc. reported significantly increased net losses and a critical cash position for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its clinical pipeline and pursuing new financing.

TuHURA Biosciences reported a widened net loss in Q2 2025, driven by increased R&D and administrative expenses, while advancing its clinical pipeline and completing the Kineta merger.

TuHURA Biosciences announced its financial results for the first quarter of 2025, highlighting ongoing preparations for a Phase 3 trial of IFx-2.0 and the pending merger with Kineta, Inc.

TuHURA Biosciences, formerly Kintara Therapeutics, released its first quarterly report post-merger, detailing financial results and operational updates including the re-initiation of the REM-001 clinical trial.

Kintara Therapeutics announced its Q3 2024 financial results, highlighted by a merger agreement with TuHURA Biosciences and the restart of the REM-001 clinical trial, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.

Kintara Therapeutics reported a net loss for the second quarter of fiscal year 2024 and is shifting its focus to the REM-001 program after discontinuing development of VAL-083.